Rapid Titration With Intravenous Oxycodone for Severe Cancer Pain and Oral Conversion Ratio

被引:7
|
作者
Mercadante, Sebastiano [1 ]
Adile, Claudio
Ferrera, Patrizia
Lo Cascio, Alessio
Casuccio, Alessandra
机构
[1] La Maddalena Canc Ctr, Main Reg Ctr Pain Relief & Support Palliat Care, Via San Lorenzo 312, I-90146 Palermo, Italy
关键词
Cancer pain; Intravenous oxycodone; Opioids; Dose titration; Palliative care; MORPHINE; INTENSITY;
D O I
10.1016/j.jpainsymman.2022.09.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. to assess a dose titration with intravenous oxycodone to achieve rapid pain relief of cancer pain of severe intensity. The second objective was to provide a conversion ratio with the oral route.Methods. Cancer patients admitted for severe pain were prospectively assessed. At admission (T0) previous opioid doses were recorded. Edmonton symptom assessment scale (ESAS) was collected from T0 until the conclusion of the observation. Intravenous boluses of oxycodone were given until the initial signs of significant analgesia were detected. The effective dose was multiplied for six and given as intravenous continuous infusion. When the patient was considered stabilized the intravenous daily dose was converted to oral oxycodone using an initial ratio of 1:2. Subsequently, doses of oral oxycodone were changed according to the clinical situation.Results. Twenty-nine patients were examined. A mean effective bolus dose of oxycodone was 9.5 mg (SD 8.0) allowed to achieve a meaningful pain relief in a mean of 10.4 minutes (SD 3.3). The mean initial and the final infusion doses were 51.0 mg/day (standard deviation 40.9) and 69.7 mg/day ( standard deviation76.6), respectively. A significant change in pain intensity was observed at the different time intervals (P<0.0005). Conversion to oral route occurred after a mean of 2.7 days (standard deviation1.2) of intravenous oxycodone. The final mean conversion ratio was 1:2,12 ( standard deviation0.36).Conclusion. Rapid intravenous oxycodone dose titration resulted in rapid pain relief. The intravenous-oral conversion ratio of 1:2 is reliable. Further studies are necessary to confirm this preliminary observation. J Pain Symptom Manage 2022;64:532-536.(c) 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:532 / 536
页数:5
相关论文
共 50 条
  • [41] Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients A multicenter, open-label, randomized controlled trial (SOCIAL)
    Pan, Hongming
    Shen, Peng
    Shu, Qijin
    Lu, Liqin
    Qian, Suying
    Zhou, Yuefen
    Han, Feng
    Guo, Qunyi
    Yang, Zhiping
    Pan, Jie
    Xu, Qing
    Zhang, Peng
    Wang, Kaifeng
    MEDICINE, 2019, 98 (24)
  • [42] Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose
    Mercadante, S
    Villari, P
    Ferrera, P
    Bianchi, M
    Casuccio, A
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 27 (04) : 352 - 359
  • [43] Oral oxycodone plus intravenous acetaminophen versus intravenous morphine sulfate in acute bone fracture pain control: a double-blind placebo-controlled randomized clinical trial
    Zare M.A.
    Ghalyaie A.H.
    Fathi M.
    Farsi D.
    Abbasi S.
    Hafezimoghadam P.
    European Journal of Orthopaedic Surgery & Traumatology, 2014, 24 (7) : 1305 - 1309
  • [44] The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain
    De Conno, F.
    Ripamonti, C.
    Fagnoni, E.
    Brunelli, C.
    Luzzani, M.
    Maltoni, M.
    Arcuri, E.
    Bertetto, O.
    PALLIATIVE MEDICINE, 2008, 22 (03) : 214 - 221
  • [45] Comparison of the efficacy of Sufentanil and Morphine Titration for patient-controlled Subcutaneous Analgesia in severe advanced cancer pain
    Liu, Dong
    Li, Wei
    Chen, Li
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2023, 39 (02) : 561 - 566
  • [46] Oxycodone Controlled-Release as First-Choice Therapy for Moderate-to-Severe Cancer Pain in Italian PatientsResults of an Open-Label, Multicentre, Observational Study
    Barbara Silvestri
    Elena Bandieri
    Salvatore Del Prete
    Giovanni Pietro Ianniello
    Giuseppe Micheletto
    Mario Dambrosio
    Giovanni Sabbatini
    Luigi Endrizzi
    Alessandro Marra
    Enrico Aitini
    Angioletta Calorio
    Ferdinando Garetto
    Giuseppe Nastasi
    Francovito Piantedosi
    Vincenzo Sidoti
    Piergiorgio Spanu
    Clinical Drug Investigation, 2008, 28 : 399 - 407
  • [47] Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study
    Motoo Nomura
    Minoru Kamata
    Hiroyuki Kojima
    Kenji Hayashi
    Masasuke Kozai
    Satoshi Sawada
    Supportive Care in Cancer, 2011, 19 : 691 - 695
  • [48] Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain
    Nomura, Motoo
    Inoue, Koichi
    Matsushita, Shoko
    Takahari, Daisuke
    Kondoh, Chihiro
    Shitara, Kohei
    Ura, Takashi
    Hayashi, Kenji
    Kojima, Hiroyuki
    Kamata, Minoru
    Tatematsu, Michiko
    Hosoda, Renko
    Sawada, Satoshi
    Oka, Hisao
    Muro, Kei
    CLINICAL JOURNAL OF PAIN, 2013, 29 (06) : 487 - 491
  • [49] Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
    Ahmedzai, Sam H.
    Leppert, Wojciech
    Janecki, Marcin
    Pakosz, Artur
    Lomax, Mark
    Duerr, Heike
    Hopp, Michael
    SUPPORTIVE CARE IN CANCER, 2015, 23 (03) : 823 - 830
  • [50] Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain
    Kawana, Mariko
    Miyasato, Akime
    Funato, Miyui
    Nagatani, Keigo
    Suzuki, Norifumi
    Onoda, Chiharu
    Fujimoto, Hidenori
    Ohno, Rintaro
    Kusakabe, Ayuko
    Kiribayashi, Mio
    Nakamura, Kazuyo
    Kondo, Masayoshi
    Ozeki, Ayumi
    Okamoto, Kousuke
    Kokubun, Hideya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2023, 46 (10) : 1444 - 1450